On October 10th, 2017, Jiudian Pharmaceutical successfully landed on the Shenzhen Stock Exchange's Growth Enterprise Market, stock code: 300705. Taking the listing as a new opportunity, Jiudian Pharmaceutical strengthens its internal strength and sought a new situation. It has made all-round improvements in the fields of R&D, production, and sales, and startes a new journey of rapid and steady development.

 

 

01. After 7 years of listing, the company's performance has continued to improve and achieved continuous growth

In April this year, Jiudian Pharmaceutical released its 2023 annual financial report. The company achieved revenue of 2.693 billion yuan, setting a new record. During the seven-year period the company's revenue has doubled, and the compound growth rate of net profit attributable to the parent company has exceeded 30%.

According to the latest semi-annual report data, the company achieved revenue of 1.366 billion yuan in the first half of 2024, a year-on-year increase of 12.19%; net profit attributable to the parent company was 284 million yuan, a year-on-year increase of 43.77%. Against the background of relatively sluggish industry prosperity, the company's revenue and net profit still achieved a good growth trend, showing the company's good development resilience and potential.

 

 

02. Dedicated research and development to build a strong moat in the field of transdermal drug delivery

In 2017, when Jiudian was listed, a new product that was not very eye-catching at the time, Jiuyue @ Loxoprofen Sodium cataplasms, was accumulating strength and preparing to open up a new era. After the product was launched in 2018, the growth rate was gratifying. It has became the largest single pharmaceutical product in Hunan Province in terms of annual sales, and has established Jiudian's leading position in the field of transdermal drug delivery in China.

 

At present, the company is continuing to focus on the advantageous field of transdermal drug delivery, making multi-dimensional layout and in-depth cultivation in the field of research and development of external preparations, key raw materials and excipients, and technological innovation, and continuing to consolidate Jiudian's leading position in this advantageous track. The company currently has 4 external preparations on the market, and dozens of external preparations are under research or have been applied for production.

 

Jiudian's success is due to the company's consistent attention and emphasis on research and development. After listing, the company continues to increase its investment in research and development, builts a first-class domestic research and development laboratory, equips with cutting-edge research and development instruments and equipment, introduces high-end research and development talents such as doctors, masters, and returnees, and builts national enterprise technology centers, postdoctoral research workstations and other innovation platforms. In the past 7 years, more than 30 preparations and more than 30 APIs and excipients have been successfully launched. After these products were launched, they fed back the company's research and development innovation and industrial upgrading with excellent market performance, providing lasting and strong support for Jiudian's development.

03, strive for excellence, to create a new high ground of intelligent manufacturing in the pharmaceutical industry

Follow the pace of "new quality productivity" and make the traditional industrial line move towards "newness". In recent years, with the strong support of the capital market, Jiudian Pharmaceutical has unswervingly promoted the expansion and upgrading of production lines, striding into a new era of digital production, and creating a new model of high-quality pharmaceutical manufacturing that is "digital, intelligent, and green".

 

In 2018, the company's oral liquid preparation workshop was rated as a Hunan Province Intelligent Manufacturing Demonstration Workshop;

In 2019, the company was rated as a national green factory;

In 2020, the second phase of the intelligent workshop construction project was included in the list of Changsha Intelligent Manufacturing Special Projects;

In 2021, the newly built oral tablet workshop introduced cutting-edge production equipment from home and abroad, all equipped with an intelligent formula management system, and the degree of intelligence is first-class in China;

In 2022, the high-end preparation research and development industrial park listed as a key construction project in Hunan Province started construction that year, and was completed and put into production that year, becoming one of the domestic pharmaceutical production bases with the most advanced equipment and the highest degree of production intelligence;

In 2023, the company was successfully rated as a Hunan Province Intelligent Manufacturing Benchmark Enterprise;

In 2024, Jiudian Hongyang API Workshop 6 was rated as a Hunan Province Intelligent Manufacturing Benchmark Workshop.

04. Improve both internal and external aspects, and be determined to enhance the reputation of Jiudian brand

Taking advantage of the listing, Jiudian comprehensively enhances the core competitiveness of the enterprise, and continuously makes a loud brand voice in the fierce market competition with its strong R&D strength, excellent product quality, and good market reputation.

 

Listing is by no means the end, but a new milestone in the development of the enterprise.

Fortunately, with the firm protection and strong support of all customers and investors, Jiudian lives up to the "7" expectation, resonates with the times, and grows together with the industry.

In the next development milestone, Jiudian will not forget its original intention and stick to its mission. Jiudian believes that in this great era, with everyone's support, Jiudian's future is promising.